<SEC-DOCUMENT>0001193125-16-760828.txt : 20161107
<SEC-HEADER>0001193125-16-760828.hdr.sgml : 20161107
<ACCEPTANCE-DATETIME>20161107065002
ACCESSION NUMBER:		0001193125-16-760828
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161101
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161107
DATE AS OF CHANGE:		20161107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		161976515

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d271494d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): November&nbsp;1, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Florida
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of incorporation) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>001-12111</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-3667538</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer Identification No.)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1301 Concord Terrace</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sunrise, Florida</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>33323</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(954) 384-0175 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2016, Karl Wagner, President, Eastern Division, of MEDNAX, Inc., a Florida corporation (the &#147;Company&#148;), informed
the Company of his intent to resign from the Company in order to pursue personal opportunities. Mr.&nbsp;Wagner will continue to serve as an executive officer of the Company through December&nbsp;31, 2016. Thereafter, the Company anticipates that
Mr.&nbsp;Wagner will remain in a full-time role with the Company through early 2017 and continue to serve the Company through the first half of 2017 in a consulting role. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on November&nbsp;1, 2016, Dr.&nbsp;Michael&nbsp;D. Stanley, President, Clinical Services Division, of the Company, informed the Company
of his intent to step-down from his current position with the Company effective December&nbsp;31, 2016. The Company anticipates that Dr.&nbsp;Stanley will continue to serve the Company thereafter in a full-time role reporting to the Company&#146;s
President and Chief Operating Officer. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;7, 2016, the Company issued a press release
announcing the information set forth in Item&nbsp;5.02 of this Current Report on Form 8-K concerning the resignation of Mr.&nbsp;Wagner. A copy of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated in this Item&nbsp;7.01
by reference. The information contained in this Item&nbsp;7.01, including Exhibit 99.1, shall not be deemed &#147;filed&#148; with the Securities and Exchange Commission nor incorporated by reference in any registration statement or other document
filed by the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><I>Exhibits</I>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of MEDNAX, Inc. dated November&nbsp;7, 2016.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:&nbsp;November 7, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Vivian Lopez-Blanco</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vivian Lopez-Blanco</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Press Release of MEDNAX, Inc. dated November&nbsp;7, 2016.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d271494dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271494g90p87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Lynch </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Strategy and Investor Relations
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">954-384-0175, x 5692 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>charles_lynch@mednax.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOR IMMEDIATE RELEASE </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX
Announces Divisional Leadership Changes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FORT LAUDERDALE</B>, <B>Fla.</B>, November&nbsp;7, 2016 &#150; MEDNAX, Inc. (NYSE: MD), today announced
that Karl Wagner, President of the Company&#146;s Eastern Division, has indicated his intent to resign from the company, in order to pursue personal opportunities. Mr.&nbsp;Wagner, who joined MEDNAX in 1997 and previously served as the
Company&#146;s Treasurer, Chief Financial Officer and President of MEDNAX&#146;s American Anesthesiology Division, will remain in his full-time position through early 2017 and serve on a consulting basis through the first half of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I want to thank Karl for all the contributions he has made to MEDNAX over the last nineteen years,&#148; said Roger J. Medel, M.D., Chief Executive
Officer of MEDNAX. &#147;In the financial and operating roles he has played, Karl has been an integral part of the growth, strategic evolution, and success we have achieved as an organization.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;After nineteen years at MEDNAX, I have decided that the time is right to take a step back and determine the next opportunity to pursue,&#148; said
Mr.&nbsp;Wagner. &#147;I have the highest confidence in the ability of my associates and friends at MEDNAX to execute on the strategy we have undertaken. I also believe the Company&#146;s focus on improving the care of our patients while bringing
solutions to our partners is exactly the right plan. I will always take with me the wonderful stories of how we have impacted an untold number of families both from the contributions of the organization as a whole or the individual care provided by
our clinicians.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separately, David Clark, President of MEDNAX&#146;s Western Division, has been named President, MEDNAX Physician Services, which
encompasses leadership of the Company&#146;s Clinical Services, Eastern and Western Divisions. Mr.&nbsp;Clark joined MEDNAX in 2001 and served as Chief Operating Officer of the Company&#146;s Pediatrix Division from 2008 until 2015. He served as
Senior Vice President, Operations, from 2003 to 2008 and as Vice President, Operations, South Central Region, from 2001 to 2003. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT MEDNAX </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. is a national health solutions partner comprised of the nation&#146;s leading providers of physician services. Physicians and advanced
practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telemedicine to enhance patient outcomes and
provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional corporations, MEDNAX provides services through a network of more than 3,600 physicians in all 50 states and Puerto Rico. In
addition to its national physician network, MEDNAX provides services to healthcare facilities and physicians in over 40 states through two complementary businesses, consisting of a revenue cycle management company and a consulting services company.
Additional information is available at www.mednax.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g271494g90p87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271494g90p87.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !> 5$# 2(  A$! Q$!_\0
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M]-=3VVGQN]O"TK$3R*I/3/('\_I6X;O4GU"(&_G^TRPK,+X2OY2.87EVA/\
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M=W,ES<2-)-*Y=W;JQ/4U%178<8JJSL%52S,<  <DU[_\/O"2^&-##3H/M]T
M]P>Z^B?A_/-</\)_"0O[P^(+Q 8+9]MNA_CD[M^'\_I7L=<6(J7?(CMP].RY
MF%%%%<AU!1110!X9\7?^1U_[=4_FU</7<?%W_D=?^W5/YM7#UZM+X$>94^-G
MK'P;MXKK2-;MYXUDBE=$=&Z,"K9%<+XQ\,R^%M>ELFRUN_SVTA_B3_$=#7??
M!/\ X\=7_P"NL?\ (UU?CGPM'XIT%X$51>09DMG/][NOT/3\JYO:<E9WV.CV
M?/25MSYXK=\'^&IO%&O16*[E@7Y[B0?P(.OXGH*QOL\PN?LQB?S]_E^7CYMV
M<8QZYKZ"\"^%4\+:"D,B@WMQB2Y<?WNR_0=/SK:M4Y(Z;F-*GSRUV.3^,=O#
M::%HUM;QK'%%*R(B]% 4 "O):]?^-?\ R"]*_P"N[_\ H->048?^&%?XPK63
MPKXAD1730[]E895A;L01Z]*R3]T_2OJ#2?\ D#67_7O'_P"@BBM5=.U@I4U.
M]SYV_P"$2\2?] '4/_ =O\*/^$2\2?\ 0!U#_P !V_PKZ4HKG^M2[&_U:/<\
M7CTZ^TSX/:I#?VDUK(U\C!)D*DC*<X->>5[W\5/^1"O/^ND7_H8KP2NBA+F3
M?F85H\K2-#0/^1BTW_K[B_\ 0Q7TW7S)H'_(Q:;_ -?<7_H8KZ:R/45ABMT;
MX;9BUGZ_>Q:;H%_>3$!(K=SSW..!^)Q3]0UG3-*A:6_OX+95&3YC@'\!U->.
M_$'X@CQ(HTS3 Z:<C;G=AAIR.G'91^M8TZ;F_(UJ5%%'!T45>T72YM;UBUTV
MW&7N) N?[H[G\!DUZ;=E<\U*[.J\7G[-X \)V+<.T3S%?8X(/_CU<2GWU^HK
MJ/B)JL.H^)C;6C9M--B6TBQT.WJ?SX_"N73[Z_45%->Z:5'[Q[;\2/!/]O:<
M-4L(LZC;1\JHYG0=OJ.WY5XCC'7BOJA/N+]!7D'Q2\$_89W\0:;%BVE;_2HU
M'^K8_P ?T/?W^M<V'J_99T5Z5_>1YL"000<$=".U.EEDGF>:5R\DC%F9NK$]
M33**[3C"BBB@ KVSX>W_ (>\/^%+>&?6;".ZG)FG5IU!!/0'GL,#\Z\3HQ6=
M2GSJUS2G/D=SV;XDWWA_7O"SBVUBQEN[1Q-"JSJ6;LRCGN#^@KQFC%%%.'(K
M7%4GSNY=T?4YM&U>UU*#[]M*'QZCN/Q&17TQ9W<-]90W=NP:*>,2(?4$9%?+
M5>T_"'7?MV@RZ3*^9;!LIGO&W(_(Y_2L,3"ZYC?#SL^4]!Z5X5\2O%__  D.
ML?8K23.GV3%5(/$K]V^G8?\ UZ[?XI>+_P"Q],_L>REQ>WB?.RGF*+H?Q/0?
MC7B=3AZ?VV/$5/LH**MZ7IEUK&IP:?9)OGG;:H/0>I/L.M1WEI/87DUG=1F.
M>!RCJ>Q%=EU>QRV=KG8_#+Q=_8.K_P!G7DF+"]8 D](I.@;Z'H?P]*]SKY4K
MW#X8>+O[<TK^R[R3-]9* "QYECZ _4=#^%<>(I_;1UX>I]EG=T445QG6%%%%
M 'AGQ=_Y'7_MU3^;5P]=W\6XI7\:92)V'V9.54GN:XC[//\ \\)?^^#7J4G[
MB/,J+WV>L?!/_CQU?_KK'_(UZ?7F7P5C>.QU;>C+F6/&X$=C7IM<%;^(SNH_
M CFCX'TP^-!XEQ^\"9\G;\OF]/,^N/UYKI:**S;;W-$DMCS/XV?\@O2O^N[_
M /H->05[!\:4>32]+"(S8G?[H)_AKR/[//\ \\)?^^#7H8?^&C@K_&1UI+XD
MUU$5$UJ_55& !<N !^=4?L\__/"7_O@T?9Y_^>$O_?!K=V>YBKK8T/\ A)M?
M_P"@YJ'_ ($O_C1_PDVO_P#0<U#_ ,"7_P :S_L\_P#SPE_[X-'V>?\ YX2_
M]\&E:([R+5UK>K7L!@N]4O+B)L$QRSLRG'L35&I/L\__ #PE_P"^#1]GG_YX
M2_\ ?!IJR$[L8"0<@X([BG_:)_\ GO)_WV:/L\__ #PE_P"^#1]GG_YX2_\
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M!^M:UM+)-;1R2PF"1ERT;$$J?3(H EHK(A\00S>()-($3 H"!-GY68 $KCU
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MUF2TM66:1#E06/"Y]:W;FSMKV+RKJWCG3^[(H846MG;647E6MO' G]V-0HH
MQ]:@BNO$&DV\RAXY8[A64]P4%9%I+/;>(-+T6Z+-)8S2>5(?^6D10[3]1TKL
M7@B>6.9XU:2/.QB.5SUQ37M+>2X2Y>"-IHQA)"OS*/8T 4-<M=/O(X8;R\^R
M3!]]O*) C*P[C/7Z57\.:A=7,M]9W-PEX+.0*ET@P) 1T..,CVK5N[&TOXPE
MW;13J#D"1 V*?;VT%I"(;:%(8QT1% % $M<HT&HW'B[54T^]CM?W4/F,T6\X
MQVYXKJZC6WA2=YUB199  [@<L!TR: *NFV$&AZ4MNKDQPJ6>1NI/4DUQK1ZS
M>:5<ZI%81%)[C[:DQEQ(H3[H"_0?K7?21I-&T<BAT<892."*1(HXXA$B*L:K
MM" < >F* *,UW'?>');N(Y2:U9Q^*FN3T^.>*RT&34KHR:6Y!1%4*(I/X-Q[
MBNXCM8(;;[-'"B0X(\L#"X/48IK6-HUH+1K:(VX  B*C:/PH ED_U3_[IK#\
M%?\ (K6OU?\ ]#-;N!MVXXQC%,@MX;6$0V\2Q1KT5!@"@#G]5T^'5/$SV4_W
M9=-89[J?,&"/H:I:+>7%QXIM[>]!%Y9VDD,W^UAAAOQ%=;Y$7G_:/+7S0NS?
MCG;G.,^E-^R6XNC=""/SRNTR[1NQZ9H P?$ZJ^KZ.K7K60+2_OU8 K\OJ>.>
MGXUKZ2BI9[5U%M0&\_OF96/TR.*ENK"SO@HN[:*<)]WS%#8IUM:6UE%Y5K!'
M#'G.V-<#/K0!QMU#J30Z[-:W3"V6\87%ND8WNF!N(;L<5UVF_9?[-MOL1!MO
M+7RL'/RXXJ:.WAB\SRXD7S6+/@?>/J:(+>&UA$-O$L4:]$08 H DHHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
